 |
5 Products |  |
0 Diseases | | 5 Products |
|
6 Trials |  |
106 News |  |
| «123 |
- |||||| adagloxad simolenin (OBI 822) / OBI Pharma
Enrollment open: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC (clinicaltrials.gov) - Dec 11, 2018
P3, N=668, Recruiting, Sponsor: OBI Pharma, Inc
Not yet recruiting --> Recruiting
- | adagloxad simolenin (OBI 822) / OBI Pharma
Trial completion date, Trial primary completion date: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC (clinicaltrials.gov) - Sep 21, 2018
P3, N=668, Not yet recruiting, Sponsor: OBI Pharma, Inc
Not yet recruiting --> Recruiting Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2025 --> Nov 2025
- | adagloxad simolenin (OBI 822) / OBI Pharma
New P2 trial, Combination therapy: Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype (clinicaltrials.gov) - Aug 1, 2018
P2, N=51, Not yet recruiting, Sponsor: Chang Gung Memorial Hospital
- | OBI-3424 / OBI Pharma
New P1/2 trial, Metastases: A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors (clinicaltrials.gov) - Jul 18, 2018
P1/2, N=92, Recruiting, Sponsor: OBI Pharma, Inc
- ||| OBI-888 / OBI Pharma
New P1 trial, Metastases: This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - Jul 15, 2018
P1, N=58, Recruiting, Sponsor: OBI Pharma, Inc
- OBI-833 / OBI Pharma
Enrollment change, Trial primary completion date, Metastases: Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects (clinicaltrials.gov) - Jan 11, 2018
P1, N=25, Recruiting, Sponsor: OBI Pharma, Inc
Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2025 --> Nov 2025 N=58 --> 25 | Trial primary completion date: Dec 2017 --> Dec 2018
- || adagloxad simolenin (OBI 822) / OBI Pharma
Trial primary completion date, Metastases: Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects (clinicaltrials.gov) - Feb 11, 2017
P2, N=349, Active, not recruiting, Sponsor: OBI Pharma, Inc
N=58 --> 25 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2016 --> Aug 2016
- || OBI-833 / OBI Pharma
Enrollment change, Metastases: Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects (clinicaltrials.gov) - Dec 1, 2016
P1, N=58, Recruiting, Sponsor: OBI Pharma, Inc
Trial primary completion date: Dec 2016 --> Aug 2016 N=26 --> 58
- || adagloxad simolenin (OBI 822) / OBI Pharma
Trial primary completion date, Metastases: Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects (clinicaltrials.gov) - Sep 15, 2016
P2, N=349, Active, not recruiting, Sponsor: OBI Pharma, Inc
N=26 --> 58 Trial primary completion date: Mar 2016 --> Dec 2016
- OBI-833 / OBI Pharma
Trial primary completion date, Metastases: Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects (clinicaltrials.gov) - Sep 13, 2016
P1, N=26, Recruiting, Sponsor: OBI Pharma, Inc
Trial primary completion date: Mar 2016 --> Dec 2016 Trial primary completion date: Nov 2016 --> Dec 2017
- || adagloxad simolenin (OBI 822) / OBI Pharma
Trial primary completion date, Metastases: Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects (clinicaltrials.gov) - Jan 17, 2016
P2, N=349, Active, not recruiting, Sponsor: OBI Pharma, Inc
Trial primary completion date: Nov 2016 --> Dec 2017 Trial primary completion date: Aug 2016 --> Mar 2016
- OBI-833 / OBI Pharma
Enrollment open, Metastases: Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects (clinicaltrials.gov) - Jan 6, 2016
P1, N=26, Recruiting, Sponsor: OBI Pharma, Inc
Trial primary completion date: Aug 2016 --> Mar 2016 Not yet recruiting --> Recruiting
- OBI-833 / OBI Pharma
Trial initiation date, Trial primary completion date, Metastases: Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects (clinicaltrials.gov) - Nov 5, 2015
P1, N=26, Not yet recruiting, Sponsor: OBI Pharma, Inc
Not yet recruiting --> Recruiting Initiation date: Mar 2015 --> Dec 2015 | Trial primary completion date: Jun 2016 --> Nov 2016
- | OBI-833 / OBI Pharma
New P1 trial, Metastases: Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects (clinicaltrials.gov) - Dec 8, 2014
P1, N=26, Not yet recruiting, Sponsor: OBI Pharma, Inc
- ||| adagloxad simolenin (OBI 822) / OBI Pharma
Enrollment closed, Trial primary completion date, Metastases: Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects (clinicaltrials.gov) - Aug 15, 2014
P2, N=342, Active, not recruiting, Sponsor: OBI Pharma, Inc
Initiation date: Mar 2015 --> Dec 2015 | Trial primary completion date: Jun 2016 --> Nov 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Aug 2016
- ||||| adagloxad simolenin (OBI 822) / OBI Pharma
New P2 trial: Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer (clinicaltrials.gov) - May 5, 2014
P2, N=110, Recruiting, Sponsor: Mackay Memorial Hospital
- ||||| adagloxad simolenin (OBI 822) / OBI Pharma
New P2 trial, Metastases: Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects (clinicaltrials.gov) - Jan 22, 2012
P2, N=342, Recruiting, Sponsor: OBI Pharma, Inc